Pluto Biosciences, Inc

GSE126794: RalA and RalB are potential therapeutic targets in multiple myeloma which mediate cell survival independently of oncogenic RAS

Bulk RNA sequencing

NRAS and KRAS are frequently mutated oncogenic drivers in multiple myeloma, however, their use as drug targets has not been successful. Hence, we reached out to characterize the role of the RAS-like (RAL) oncogenic signaling cascade and compare transcriptomic changes after knockdown af KRAS and RALA. SOURCE: Claus,Juergen,Scholz University Hospital Würzburg

View this experiment on Pluto Biosciences, Inc